Sangamo Therapeutics (NASDAQ:SGMO) Earns “Buy” Rating from HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a note issued to investors on Tuesday,Briefing.com Automated Import reports. They presently have a $10.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 423.56% from the company’s previous close.

Other analysts have also recently issued research reports about the company. StockNews.com cut Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Barclays lifted their target price on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th.

Sangamo Therapeutics Price Performance

Shares of NASDAQ:SGMO traded down $0.09 on Tuesday, reaching $1.91. 1,990,789 shares of the company traded hands, compared to its average volume of 6,792,716. The stock has a market capitalization of $398.52 million, a PE ratio of -2.55 and a beta of 1.15. The company’s 50 day moving average is $1.71 and its 200-day moving average is $1.03. Sangamo Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.07. The business had revenue of $49.41 million for the quarter, compared to the consensus estimate of $26.55 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. During the same period last year, the firm posted ($0.34) earnings per share. As a group, analysts expect that Sangamo Therapeutics will post -0.46 EPS for the current year.

Institutional Trading of Sangamo Therapeutics

A number of large investors have recently bought and sold shares of the business. Meritage Portfolio Management boosted its stake in shares of Sangamo Therapeutics by 8.6% during the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 6,740 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in Sangamo Therapeutics by 55.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 38,850 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Sangamo Therapeutics by 5.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock valued at $956,000 after buying an additional 57,125 shares during the last quarter. XTX Topco Ltd raised its stake in Sangamo Therapeutics by 167.8% in the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 64,981 shares during the period. Finally, Golden State Equity Partners raised its position in shares of Sangamo Therapeutics by 35.2% in the third quarter. Golden State Equity Partners now owns 266,484 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 69,368 shares during the period. 56.93% of the stock is owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.